'Mmol' diaporamas de présentation

Electrolytes, Fluids, Acid Base Balance and Shock

Electrolytes, Fluids, Acid Base Balance and Shock. Gwynne Jones Critical Care. Electrolytes, Fluids, Acid Base Balance and Shock. Correct Fluid Management faqcilitatescrucial Homeostasis. This permits: Optimum Cardio-vascular perfusion Optimum Organ Function Optimum Cellular Function.

1.4k views • 111 slides

???????????

???????????. ??? ?????????. ?. ?????????. . 1. ?? ???????. ??? ? volatile acid?? H 2 CO 3 H 2 CO 3 ? CO 2 ? CO 2 ??????(?????). ??? ( fixed acid? ???? )? ????????,??????????????? ???? H 2 SO 4 ? ???. ?? ??????????? ???.

1.23k views • 102 slides

Moonlight Medicine

Moonlight Medicine. Laboratory Interpretation. Adrian Paul J Rabe, MD, DPCP. Laboratory Interpretation. Supplements the history and physical examination Objective evidence of disease/health. Laboratory Interpretation. Complete blood count Bleeding tests PT/PTT, Bleeding time

820 views • 60 slides

717 views • 57 slides

DIABETIC KETOACIDOSIS

DIABETIC KETOACIDOSIS. DIABETIC KETOACIDOS IS A MAJOR MADICAL EMERGENCY AND REMAINS A SERIOUS CAUSE OF MORBIDITY PRINCIPALLY IN PEOPLE WITH TYPE 1 DM. IT IS DEFINED AS

1.82k views • 42 slides

??? ???? ?????? ??????

??? ???? ?????? ??????. SIADH 23.11.1423. BACKGROUND. # AVP, THE NATURAL HUMAN ADH # SYNTHESTISED IN THE ANT . HYPOTHALAMUS & STORED IN THE POS. PITUITARY # ADH RELEASING RECEPTORS 1.OSMORECEPTORS 2-BARORECEPTORS. ACTION OF ADH.

550 views • 39 slides

Pn Syazni Zainul Kamal PPK Bioproses

Chapter 4 : Classical Methods in Techniques of Analytical Chemistry : Titrimetric Methods of Analysis. Pn Syazni Zainul Kamal PPK Bioproses. CO4: ABILITY TO DIFFERENTIATE AND CALCULATE CONCENTRATION OF ANALYTES OF VARIOUS TITRIMETRIC METHODS (ACID-BASE, COMPLEXATION, REDOX, PRECIPITATION).

830 views • 38 slides

ANALYTICAL CHEMISTRY CHEM 3811 CHAPTER 10

561 views • 36 slides

Collaborative Atorvastatin Diabetes Study CARDS

Collaborative Atorvastatin Diabetes Study CARDS. Helen Colhoun, John Betteridge, Paul Durrington, Graham Hitman, Andrew Neil, Shona Livingstone, Margaret Thomason, Michael Mackness, Valentine Menys, John Fuller on behalf of the CARDS Investigators. CARDS The Rationale.

650 views • 35 slides

The Anglo-Scandinavian Cardiac Outcomes Trial

563 views • 30 slides

6-4-2011

446 views • 27 slides

Rationale

358 views • 26 slides

Plasma Lipids at diagnosis of Type 2 Diabetes

UKPDS. MEN. WOMEN. Type 2. Control. Type 2. Control. N. 2139. 52. 1574. 143. TC mmol/l (mg/dl). 5.5 (213). 5.3 (205). 5.8 (224). 5.6 (217). LDL-C mmol/l (mg/dl). 3.6 (139). 3.4 (132). 3.9 (151). 3.5 (135). HDL-C mmol/l (mg/dl). 1.0 (39). 1.1 (43). 1.1 (43). 1.4 (55).

310 views • 20 slides

Plasma Lipids at diagnosis of Type 2 Diabetes

UKPDS. MEN. WOMEN. Type 2. Control. Type 2. Control. N. 2139. 52. 1574. 143. TC mmol/l (mg/dl). 5.5 (213). 5.3 (205). 5.8 (224). 5.6 (217). LDL-C mmol/l (mg/dl). 3.6 (139). 3.4 (132). 3.9 (151). 3.5 (135). HDL-C mmol/l (mg/dl). 1.0 (39). 1.1 (43). 1.1 (43). 1.4 (55).

330 views • 20 slides

Example

Example. A 0.4671 g sample containing Na 2 CO 3 (FW = 106mg/mmol) was dissolved and titrated with 0.1067 M HCl requiring 40.72 mL. Find the percentage of carbonate in the sample. The equation should be the first thing to formulate Na 2 CO 3 +2 HCl g 2NaCl + H 2 CO 3

508 views • 16 slides

pH calculations 1. Strong Acids and Strong Bases

We are faced with different types of solutions that we should know how to calculate the pH or pOH for. These include calculation of pH for 1. Strong acids and strong bases 2. Weak acids (monoprotic) and weak bases (monobasic) 3. Salts of weak acids and salts of weak bases

401 views • 15 slides

Industry Relationships and Institutional Affiliations

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia ( h eFH ) not adequately controlled with current lipid-lowering therapy: Results of ODYSSEY FH I and FH II studies.

252 views • 13 slides

Dr Ahmad abanamy hospital Dr Nuaman danawar general& gastrointestinal surgeon

214 views • 13 slides

pERK1/2

A. pERK1/2. ERK1/2. ?. 2.0. 1.5. ERK 1/2 phosphorylation (fold). 1.0. 0.5. 0. 137.5. 137.5 +Ang II. 137.5. 137.5 +Ang II. mmol/L. HMA (30 ? mol/L). B. ?. 2.0. 1.5. [ 3 H]- thymidine incorporation (fold). 1.0. 0.5. 0. 137.5. 137.5 +Ang II. 137.5. 137.5 +Ang II.

188 views • 2 slides

pNHE-1

IP: pSer 14-3-3. pNHE-1. pSer 14-3-3. ?. ?. 2.0. 1.5. NHE-1 phosphorylation (fold). 1.0. 0.5. 0. 137.5 +Ang II. 140 +Ang II. mmol/L. 137.5. 140. Supplementary Figure 2.

108 views • 1 slides